Value of NOTCH1 Screening in CLL
Patients with NOTCH1 mutations benefit more from BTK inhibitor treatment than from immunochemotherapy for chronic lymphocytic leukemia (CLL).
CLL is a common hematologic malignancy, and treatment decisions depend on molecular features, including TP53 and IGHV mutational status.
Research suggests that NOTCH1 mutations may serve as a biomarker for selecting Bruton tyrosine kinase inhibitors (BTKi) therapy.
NOTCH1 is one of the most frequently mutated genes in CLL, present in approximately 20% of newly diagnosed cases.
A bicentric retrospective analysis from 2 French tertiary care centers supports the importance of NOTCH1 mutations in guiding therapy.
Author's summary: NOTCH1 mutations guide CLL therapy.More News
- Hamilton urges Ferrari to make 'personnel changes' ahead of F1 2026
- Jay Kelly cast guide: All on which characters George Clooney, Adam Sandler and Laura Dern play in the film
- Jack Osbourne breaks silence on jungle feud with Kelly Brook
- Pelicans' Questionable Offseason Trade Looks Better After Saddiq Bey's Rise
- How to watch Islanders vs. Lightning: TV channel and streaming options for December 6
- F1 2026 : Lancements, livrées et premiers indices d'une révolution en piste
- How former Gonzaga stars perform in NBA
- Lando Norris wins his first F1 title despite Max Verstappen victory: Live updates and reaction
- Spurs' Kelly Olynyk: Ongoing Decline in Playing Time and Role
- JUST IN: Kelly Olynyk has been waived by the San Antonio Spurs